Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTANIL vs SELEXIPAG
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Selective agonist of the prostacyclin (IP) receptor, causing vasodilation and inhibition of platelet aggregation via increased c AMP levels.
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Treatment of pulmonary arterial hypertension (PAH; WHO Group I) to improve exercise capacity and delay clinical worsening.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Oral, starting dose 200 mcg twice daily, titrated in increments of 200 mcg twice daily at weekly intervals as tolerated to a maximum of 1600 mcg twice daily.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Terminal elimination half-life is approximately 6–8 hours following intravenous administration; with oral administration, the effective half-life is ~6–9 hours due to enterohepatic recirculation; clinical context: dosing every 6 hours is required to maintain therapeutic plasma concentrations.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Primarily metabolized by CYP2C8 and CYP3A4; minor contribution from UGT1A3, UGT2B7, and CYP2C9.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Primarily hepatic metabolism (approximately 97% of dose) via CYP2C8 and CYP3A4; biliary/fecal excretion of metabolites accounts for ~77% of total clearance; renal excretion <1% as unchanged drug.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Approximately 99% bound to plasma proteins, primarily albumin.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Volume of distribution at steady state is approximately 1.7 L/kg (range 1.1–2.5 L/kg), indicating extensive extravascular distribution.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
Oral bioavailability is approximately 90% under fed conditions; absorption is delayed and reduced by high-fat meals, but overall systemic exposure is increased by ~30% compared to fasting.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <15 m L/min/1.73 m²) or on dialysis; use with caution.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B, reduce starting dose to 200 mcg once daily and titrate cautiously; monitor closely.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Not approved for pediatric use; safety and efficacy not established.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
No specific dose adjustment recommended; initiate at 200 mcg twice daily and titrate based on tolerability, considering increased sensitivity and comorbidities.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Not recommended for use in patients with severe hepatic impairment (Child-Pugh class C).
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Elderly patients may have increased exposure.,Patients with hepatic impairment: dose adjustment required for moderate impairment; avoid in severe impairment.,Concomitant use with strong CYP2C8 inhibitors (e.g., gemfibrozil) increases selexipag exposure by 11-fold; reduce dose.,Concomitant use with strong CYP3A4 inducers (e.g., rifampin) reduces exposure; monitor efficacy.,May cause headache, diarrhea, jaw pain, flushing, and nausea.
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Severe hepatic impairment (Child-Pugh class C).,Concomitant use with strong CYP2C8 inhibitors (e.g., gemfibrozil).
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
Take with food to improve tolerance. Avoid grapefruit and grapefruit juice as they may increase selexipag plasma concentrations. No other significant food interactions known.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Selexipag is contraindicated in pregnancy. Animal studies show increased post-implantation loss and reduced fetal weights. No adequate human data; based on its mechanism (IP receptor agonist), risk of fetal harm cannot be excluded, particularly in the first trimester.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
No data on selexipag in human milk. In animal studies, selexipag is excreted in rat milk. M/P ratio unknown. Breastfeeding is not recommended during treatment and for at least 7 days after last dose.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
Selexipag is not recommended in pregnancy. No dose adjustment data exist; pharmacokinetics in pregnancy have not been studied. Theoretical changes in volume of distribution and hepatic clearance may require monitoring, but no specific adjustments are established.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Selexipag is a prostacyclin receptor (IP receptor) agonist used for pulmonary arterial hypertension (PAH). It is a prodrug that requires hepatic carboxylesterase 1 (CES1) activation. Monitor for signs of pulmonary edema suggestive of pulmonary veno-occlusive disease. Concurrent use with strong CYP2C8 inhibitors (e.g., gemfibrozil) increases exposure and is contraindicated. Dose adjustment needed in moderate hepatic impairment (Child-Pugh B). Thyroid abnormalities and bleeding risk are potential concerns.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
Take selexipag exactly as prescribed, typically twice daily with food to reduce gastrointestinal side effects.,Do not crush or chew tablets; swallow whole.,Common side effects include headache, diarrhea, nausea, jaw pain, and muscle aches; report persistent or severe symptoms.,Avoid grapefruit juice as it may increase drug levels.,Inform your doctor if you experience signs of bleeding (unusual bruising, nosebleeds) or thyroid issues (fatigue, weight changes).,Do not stop abruptly without medical advice; sudden discontinuation may worsen PAH.,If you are taking gemfibrozil or other CYP2C8 inhibitors, discuss with your doctor as combination is contraindicated.,Women of childbearing potential should use effective contraception; discuss pregnancy planning with your doctor.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
"Hydrochlorothiazide, a thiazide diuretic, reduces blood pressure primarily by decreasing plasma volume and cardiac output, while Selexipag, a prostacyclin receptor agonist, causes vasodilation and inhibits platelet aggregation. Their concomitant use results in additive hypotensive effects, increasing the risk of symptomatic hypotension, dizziness, and syncope. This interaction is particularly significant in patients with compromised baroreflex function or those receiving other antihypertensives."
"Selexipag, a prostacyclin receptor agonist used for pulmonary arterial hypertension, is primarily metabolized by CYP2C8 and CYP3A4. Abiraterone, a CYP3A4 inhibitor, may reduce the clearance of selexipag, leading to increased selexipag exposure. This can potentiate its adverse effects such as headache, flushing, and hypotension, though the impact on abiraterone levels is minimal due to abiraterone's multiple metabolic pathways."
"Bretylium, an antiarrhythmic agent, exerts sympatholytic effects by blocking norepinephrine release from adrenergic nerve terminals, leading to peripheral vasodilation and potential hypotension. Selexipag, a prostacyclin receptor agonist used for pulmonary arterial hypertension, also induces vasodilation via activation of IP receptors in vascular smooth muscle. When coadministered, the vasodilatory effects are additive, increasing the risk of clinically significant hypotension, which may manifest as dizziness, syncope, or impaired organ perfusion."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTANIL vs SELEXIPAG, answered by our medical review team.
ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. SELEXIPAG is a Prostacyclin Receptor Agonist that works by Selective agonist of the prostacyclin (IP) receptor, causing vasodilation and inhibition of platelet aggregation via increased c AMP levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTANIL and SELEXIPAG depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. The standard adult dose of SELEXIPAG is: Oral, starting dose 200 mcg twice daily, titrated in increments of 200 mcg twice daily at weekly intervals as tolerated to a maximum of 1600 mcg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTANIL and SELEXIPAG in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. SELEXIPAG is classified as Category C. Selexipag is contraindicated in pregnancy. Animal studies show increased post-implantation loss and reduced fetal weights. No adequate human data; based on its mechanism (IP recept. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.